Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Standard BioTools (LAB)
NASDAQ:LAB
Holding LAB?
Track your performance easily
LAB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.21 - $3.04
Previous Close$1.62
Volume2.13M
Average Volume (3M)1.85M
Market Cap
$603.06M
Enterprise Value$326.20M
Total Cash (Recent Filing)$366.33M
Total Debt (Recent Filing)$89.47M
Price to Earnings (P/E)―
Beta2.05
Next Earnings
Feb 12, 2025EPS Estimate
-$0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.71
Shares Outstanding372,258,798
10 Day Avg. Volume2,395,973
30 Day Avg. Volume1,854,102
Standard Deviation0.26
R-Squared0.10
Alpha-0.00582
Financial Highlights & Ratios
Price to Book (P/B)1.23
Price to Sales (P/S)3.61
Price to Cash Flow (P/CF)-5.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.09
Enterprise Value/Gross Profit6.47
Enterprise Value/Ebitda-2.79
Forecast
1Y Price Target
$2.50Price Target Upside46.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Standard BioTools News
PremiumCompany Announcements
Standard BioTools Names Alex Kim as New CFO
PremiumCompany Announcements
Standard BioTools Inc. Reports Q3 2024 Financial Performance
PremiumCompany Announcements
Standard BioTools Reports Strong Q3 2024 Performance
Bulls Say, Bears Say
Bulls Say
Business StrategyLAB has adopted a new strategy focused on stabilizing the business for growth, improving operating discipline, and acquiring complementary assets.
EarningsLAB reported a 9% sales beat with margins ahead and cost controls solid.
Merger And AcquisitionThe merger with SLGC nearly doubles LAB's revenues, expands the TAM & strengthens the balance sheet.
Bears Say
Financial Performance2Q revenue missed consensus, a notable miss after a solid 1Q where management reiterated FY'24 guidance.
Management ChangesExpect shares to be weak NT post a 2Q miss, material '24 guide cut & a CFO departure.
Operational ChallengesThe biggest driver of the miss was from SomaScan Assay Services where contract timing delays from a large pharma customer led to a revenue delay.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
LAB FAQ
What was Standard BioTools’s price range in the past 12 months?
Standard BioTools lowest stock price was $1.21 and its highest was $3.04 in the past 12 months.
What is Standard BioTools’s market cap?
Currently, no data Available
When is Standard BioTools’s upcoming earnings report date?
Standard BioTools’s upcoming earnings report date is Feb 12, 2025 which is in 77 days.
How were Standard BioTools’s earnings last quarter?
Standard BioTools released its earnings results on Oct 30, 2024. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.09 by $0.02.
Is Standard BioTools overvalued?
According to Wall Street analysts Standard BioTools’s price is currently Undervalued.
Does Standard BioTools pay dividends?
Standard BioTools does not currently pay dividends.
What is Standard BioTools’s EPS estimate?
Standard BioTools’s EPS estimate is -$0.06.
How many shares outstanding does Standard BioTools have?
Standard BioTools has 372,258,800 shares outstanding.
What happened to Standard BioTools’s price movement after its last earnings report?
Standard BioTools reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.09. Following the earnings report the stock price went up 4.255%.
Which hedge fund is a major shareholder of Standard BioTools?
Among the largest hedge funds holding Standard BioTools’s share is Viking Global Investors LP. It holds Standard BioTools’s shares valued at 113M.
---
Standard BioTools Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.50 (46.20% Upside)
$2.50 (46.20% Upside)
Blogger Sentiment
Bullish
LAB Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 3.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.9%
Last 30 Days ▼ 8.9%
Last 30 Days ▼ 8.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.60%
12-Months-Change
Fundamentals
Return on Equity
-69.68%
Trailing 12-Months
Asset Growth
100.88%
Trailing 12-Months
Company Description
Standard BioTools
Fluidigm Corp. is engaged in the development, manufacture and marketing of biotechnology tools fro life sciences research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics; and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen R. Quake and Gajus V. Worthington on May 19, 1999 and is headquartered in South San Francisco, CA.
---
LAB Company Deck
---
LAB Earnings Call
Q3 2024
0:00 / 0:00
---
LAB Stock 12 Month Forecast
Average Price Target
$2.50
▲(46.20% Upside)
Technical Analysis
Best Analysts Covering LAB
1 Year
1 Year Success Rate
2/7 ratings generated profit
1 Year Average Return
-8.47%
assigned a buy rating 27 days ago
Copying Daniel Brennan's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -8.47% per trade.
---